--- title: "U.S. stock market midday update: Adlai Nortye up 9.38%, active funds, sector trends driving volatility" type: "News" locale: "en" url: "https://longbridge.com/en/news/291834111.md" description: "Adlai Nortye rose by 9.38%; Moderna rose by 2.46%, with a transaction volume of USD 784 million; AbbVie fell by 2.03%, with a transaction volume of USD 700 million; Gilead Sciences fell by 1.66%, with a transaction volume of USD 636 million; Amgen fell by 2.29%, with a market value of USD 197.3 billion" datetime: "2026-07-06T18:17:25.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/291834111.md) - [en](https://longbridge.com/en/news/291834111.md) - [zh-HK](https://longbridge.com/zh-HK/news/291834111.md) generator: "portal-rs" --- # U.S. stock market midday update: Adlai Nortye up 9.38%, active funds, sector trends driving volatility **U.S. Stock Market Midday Update** Adlai Nortye, up 9.38%, with increased trading volume and no significant news recently. Trading is active, with clear capital flow. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. **Stocks with High Trading Volume in the Industry** Moderna up 2.46%. Based on recent key news: 1. On July 6, Moderna's flu vaccine received unanimous support from the FDA advisory committee, with the stock price reaching a 52-week high. The stock price continued to strengthen after updates to the vaccine pipeline, with trading volume increasing, reaching $784 million. 2. On July 4, despite the rise in Moderna's stock price, its price-to-sales ratio reached 13 times, indicating a significant trading premium. The market's pricing of the mRNA platform and approval pathway reflects a de-risking approach, but uncertainty remains. 3. On July 4, analysts believe Moderna's stock price is nearing a peak and recommend waiting for a pullback or more visibility in the post-pandemic era. The vaccine industry has performed strongly recently, with macroeconomic policies being neutral. AbbVie down 2.03%. Based on recent key news: 1. On July 6, Cantor Fitzgerald raised AbbVie's target price from $240 to $265, indicating increased market confidence in its future growth; however, the stock price still declined. 2. On July 6, the European Commission approved AbbVie's Tepkinly for second-line treatment of relapsed or refractory follicular lymphoma, but this news failed to boost the stock price, possibly due to the market's cautious stance on the long-term impact of the new drug. 3. On July 6, frequent M&A activities in the pharmaceutical industry saw AbbVie strengthen its defensive positioning through acquisitions, but the market still has concerns about its short-term financial performance, putting pressure on the stock price. The pharmaceutical industry is experiencing frequent M&A, leading to increased market volatility. Gilead Sciences down 1.66%. Based on recent key news: 1. On July 6, HSBC upgraded Gilead Sciences' rating from "Hold" to "Buy," raising the target price from $133 to $155. This rating upgrade reflects market confidence in Gilead's future performance, yet the stock price still declined. 2. On July 6, MarketBeat reported that Gilead Sciences was not included in the list of top five stocks recommended by leading analysts, despite its rating being "Moderate Buy." This news may lead some investors to doubt Gilead's market prospects, affecting the stock price. 3. On July 4, Benzinga reported that Gilead Sciences had an annualized return of 11.3% over the past 20 years, outperforming the market average. However, the long-term performance has not alleviated the pressure from the recent stock price decline. The market lacks confidence in Gilead's future performance, with noticeable capital outflows. **Stocks with High Market Capitalization in the Industry** Amgen fell 2.29%. Based on recent key news: 1. On July 6, analysts raised the average target price for Amgen to $355.04, although there remains about 5% potential downside. The analysts' buy rating remains unchanged, and market confidence in its future performance has strengthened. 2. On July 4, market analysis indicated that Amgen was not included in the list of five stocks recommended by top analysts, leading to a decrease in investor confidence regarding its short-term performance. 3. On July 4, Amgen's hold rating dominated among analysts, with the market maintaining a cautious outlook on its future growth. Recent volatility in the U.S. stock market necessitates attention to risks ### Related Stocks - [ANL.US](https://longbridge.com/en/quote/ANL.US.md) - [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [GILD.US](https://longbridge.com/en/quote/GILD.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) ## Related News & Research - [Moderna stock soars on cancer vaccine success](https://longbridge.com/en/news/296405393.md) - [If You Invested $1,000 In Moderna Stock at IPO, Here's How Much You'd Have Now](https://longbridge.com/en/news/296641626.md) - [Moderna’s 177% Surge Has Investors Asking What Comes Next](https://longbridge.com/en/news/296610623.md) - [MEXC Lists Ondo Tokenized Stock Moderna (MRNAON), Expanding Access to U.S. Biotech Exposure](https://longbridge.com/en/news/296603043.md) - [Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet.](https://longbridge.com/en/news/296643850.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**